Three or four cycles of cisplatin-based chemotherapy is the standard neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer. Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycles are also commonly administered in clinical practice. In this multicenter retrospective study, we assessed a large and homogenous cohort of patients with urothelial bladder cancer (UBC) treated with three or four cycles of neoadjuvant cisplatin-gemcitabine followed by radical cystectomy, in order to explore whether three vs. four cycles were associated with different outcomes.

Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis / Ferro, Matteo; de Cobelli, Ottavio; Musi, Gennaro; Lucarelli, Giuseppe; Terracciano, Daniela; Pacella, Daniela; Muto, Tommaso; Porreca, Angelo; Busetto, Gian Maria; Del Giudice, Francesco; Soria, Francesco; Gontero, Paolo; Cantiello, Francesco; Damiano, Rocco; Crocerossa, Fabio; Farhan, Abdal Rahman Abu; Autorino, Riccardo; Vartolomei, Mihai Dorin; Muto, Matteo; Marchioni, Michele; Mari, Andrea; Scafuri, Luca; Minervini, Andrea; Longo, Nicola; Chiancone, Francesco; Perdona, Sisto; De Placido, Pietro; Verde, Antonio; Catellani, Michele; Luzzago, Stefano; Mistretta, Francesco Alessandro; Ditonno, Pasquale; Caputo, Vincenzo Francesco; Battaglia, Michele; Zamboni, Stefania; Antonelli, Alessandro; Greco, Francesco; Russo, Giorgio Ivan; Hurle, Rodolfo; Crisan, Nicolae; Manfredi, Matteo; Porpiglia, Francesco; Di Lorenzo, Giuseppe; Crocetto, Felice; Buonerba, Carlo. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 11:article 651745(2021). [10.3389/fonc.2021.651745]

Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis

Ferro, Matteo;Musi, Gennaro;Lucarelli, Giuseppe;Terracciano, Daniela;Pacella, Daniela;Scafuri, Luca;Longo, Nicola;Chiancone, Francesco;De Placido, Pietro;Caputo, Vincenzo Francesco;Crocetto, Felice;Buonerba, Carlo
2021

Abstract

Three or four cycles of cisplatin-based chemotherapy is the standard neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer. Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycles are also commonly administered in clinical practice. In this multicenter retrospective study, we assessed a large and homogenous cohort of patients with urothelial bladder cancer (UBC) treated with three or four cycles of neoadjuvant cisplatin-gemcitabine followed by radical cystectomy, in order to explore whether three vs. four cycles were associated with different outcomes.
2021
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis / Ferro, Matteo; de Cobelli, Ottavio; Musi, Gennaro; Lucarelli, Giuseppe; Terracciano, Daniela; Pacella, Daniela; Muto, Tommaso; Porreca, Angelo; Busetto, Gian Maria; Del Giudice, Francesco; Soria, Francesco; Gontero, Paolo; Cantiello, Francesco; Damiano, Rocco; Crocerossa, Fabio; Farhan, Abdal Rahman Abu; Autorino, Riccardo; Vartolomei, Mihai Dorin; Muto, Matteo; Marchioni, Michele; Mari, Andrea; Scafuri, Luca; Minervini, Andrea; Longo, Nicola; Chiancone, Francesco; Perdona, Sisto; De Placido, Pietro; Verde, Antonio; Catellani, Michele; Luzzago, Stefano; Mistretta, Francesco Alessandro; Ditonno, Pasquale; Caputo, Vincenzo Francesco; Battaglia, Michele; Zamboni, Stefania; Antonelli, Alessandro; Greco, Francesco; Russo, Giorgio Ivan; Hurle, Rodolfo; Crisan, Nicolae; Manfredi, Matteo; Porpiglia, Francesco; Di Lorenzo, Giuseppe; Crocetto, Felice; Buonerba, Carlo. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 11:article 651745(2021). [10.3389/fonc.2021.651745]
File in questo prodotto:
File Dimensione Formato  
fonc-11-651745.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Dominio pubblico
Dimensione 1.36 MB
Formato Adobe PDF
1.36 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/853068
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact